Newer Drugs Fuel BMY’s Top Line Growth portfolio primarily comprises Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati and others. Strong growth in ...

Bristol-Myers Squibb Company BMY reported first-quarter 2025 adjusted earnings per share (EPS) of $1.80, which comfortably beat the Zacks Consensus Estimate of $1.51. In the year-ago quarter, BMY ...

The reported number represents a year-over-year change of +35%. Net Sales- Zeposia: $107 million versus the five-analyst average estimate of $119.29 million. The reported number represents a year ...

Biotech giant Bristol-Myers Squibb Company BMY is scheduled to report first-quarter 2025 results on April 24, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $ ...